Prostate-specific membrane antigen positron emission tomography (PSMA PET) findings and receipt of salvage radiation treatment (SRT) are associated with event-free survival (EFS) among men with biochemical recurrence (BCR) after radical prostatectomy (RP), according to a study published online April 29 in BJU International.
Matthew J. Roberts, M.B.B.S., Ph.D., from the Royal Brisbane and Women’s Hospital in Australia, and colleagues conducted a retrospective analysis of a study in which men with BCR after RP underwent PSMA PET. The European Association of Urology (EAU) risk groups were assessed relative to PSMA PET findings and clinical variables for 137 patients.
The researchers found that at the time of PSMA PET, most patients (76 percent) had high EAU risk and/or low prostate-specific antigen (80 percent <0.5 ng/mL). There was no association seen for EAU risk with PSMA PET regional nodal/distant metastases. There were associations observed for regional nodal/distant metastasis on PSMA PET (compared with negative/local recurrence) and SRT use (versus no use) with EFS (hazard ratios, 2.2 and 0.44, respectively); high versus low EAU was not significantly associated with worse EFS. Both regional/distant metastasis on PSMA PET and high EAU risk were independently associated with worse EFS among patients who received SRT (hazard ratios, 3.1 and 2.9, respectively); this risk was driven by high EAU-risk patients with regional/distant metastasis (38 percent; hazard ratio, 3.1).
“These findings provide early evidence for the value of PSMA PET among clinical variables for prediction of oncological outcomes in the BCR setting,” the authors write.
Source: HealthDay News